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article under the CC BY-NC-ND license (Abstract Background/purpose: The presence of adequate bone volume is a critical factor in
rehabilitative dentistry. Despite the use of many promising alloplasts, success in stimulating
bone formation has been limited, mostly due to poor local biological response. Growth factors
have been introduced to stimulate angiogenesis and new bone formation. This histologic and his-
tomorphometric study aimed to evaluate the effect of vascular endothelial growth factor (VEGF)
and a biphasic alloplastic graft material (BA) on the healing of endosseous defects in rats.
Materials and methods: TwentymaleWistar rats were used. Two critical-sized bone defects were
created in both the right and left femurs of each rat. Each defect was randomly assigned to be
treated with VEGF, BA, or VEGF þ BA, or to be left empty as a control. Half of the animals were
sacrificed after 1week, and the remaininghalfwere sacrificed after 2weeks. Inflammation, necro-
sis, and new bone areas were evaluated by means of histologic and histomorphometric analyses.
Results: Comparedto thecontrol group,defects treatedwithVEGFaloneor in combinationwithBA
showed higher rates of bone formation (33.10e46.60%) on Day 7. Additionally, VEGF significantly
reduced inflammation and necrosis (P< 0.001). However, the differences were no longer discern-
able on Day 14.
Conclusion: VEGF makes a significant contribution to angiogenesis and osteogenesis in the early
stages of bone defect healing, and its combination with an osteoconductive grafting material
(BA) may further enhance new bone formation.
Copyright ª 2016, Association for Dental Sciences of the Republic of China. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Arısan, Department of Oral Implantology, Faculty of Dentistry, Istanbul University, 34390-Capa,
du.tr (V. Arısan).
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+ MODELIntroductionBone defects caused by periodontal disease, trauma,
congenital anomalies, infection, and malignancies pose a
serious problem in dentistry.1 Despite various treatment
methods and proposed grafting materials, no treatment is
available to regenerate bone defects reliably.2 Autogenous
grafts have been used with a high success rate. However,
they create a second wound area and postoperative
morbidity.3 Furthermore, surface bone resorption was
evident in long-term follow-up studies.4 Allogenic and
alloplastic grafting materials represent a more conservative
approach, but they lack osseoinductive properties because
of the strict decontamination and sterilization procedures
involved in their production.5 Growth factors have been
used as an adjunct to these materials in stimulating new
bone formation. This combination is intended to establish a
beneficial healing environment and to recreate the former
structural integrity of the defective area in a cost-effective
and minimally invasive manner.6 Among these materials,
biphasic calcium phosphates constitute a promising alter-
native by its space-maintaining and regenerative properties
in the bone tissue.5,6
When alloplasts are used alone, their osteoinductive
characteristics have been shown to be insufficient for bone
defect repair, perhaps because they fail to elicit sufficient
vital nutrient spread in the bulk graft body.7 Concurrent
use of various growth factors has yielded better outcomes
by triggering cellular differentiation and migration within
the alloplast body.8,9 Bone replacement via alloplast needs
to be accompanied by ample vascularization because
osteoid deposition and turnover depends on several
different cell groups and phases.10 Vascularization is thus
one of the most important prerequisites for bone heal-
ing.11 In previous work, vascular endothelial growth factor
(VEGF) has been shown to stimulate local vascular regen-
eration in bone healing.12 Moreover, it has been demon-
strated that VEGF plays an important role in new bone
formation by enhancing chemotaxis of mesenchymal stem
cells and by stimulating differentiation and proliferation of
osteoblasts via an indirect effect on osteoprogenitor
cells.13 VEGF is produced by various types of cells,
including tumor cells, macrophages, platelets, keratino-
cytes, and renal mesenchymal cells.14 The functions of
VEGF are not limited to the vascular endothelial system.15
It has been stated that VEGF also plays a role in normal
physiological functions such as bone formation, hemato-
poiesis, and wound healing.16 Angiogenesis plays an
important role in endochondral ossification, the process by
which avascular cartilage tissue becomes vascular bone
tissue. During bone development, signals required for
apoptosis of hypertrophic chondrocytes in epiphyseal
growth plaques are provided by new blood vessels. Over
the course of this process, VEGF is secreted from hyper-
trophic chondrocytes; thus, growth of metaphyseal vessels
into cartilage tissue and new bone formation occurs.17
VEGF also has chemotactic effects on osteoblasts. It has
been suggested that VEGF has a role in chondrocyte death,
chondroclast function, extracellular matrix remodeling,
angiogenesis, and regulation of bone formation.18 As aPlease cite this article in press as: Bedeloglu E, et al., Vascular en
endosseous healing of femoral defects: An experimental rat study,
j.jds.2016.04.005consequence, VEGF plays an important role in both types
of bone healing.
Enhanced healing properties provided by the VEGF may
also improve osteogenesis and biodegradation of biphasic
calcium phosphates. The aim of this histologic and histo-
morphometric study was to analyze the effect of VEGF and
a biphasic alloplastic graft material (BA), when used alone
or in combination on new bone formation in a rat model.Materials and methods
Male Wistar rats (n Z 20) aged 6e8 months and weighing
between 350 g and 400 g were used. Approval of the
Istanbul University Experimental Animals Ethics Committee
(Istanbul, Turkey; No. 2010/160, Date: November 04, 2012)
was obtained, and all procedures were conducted in
accordance with the Istanbul University ethical guidelines
for the treatment and welfare of experimental animals.
The surgical procedure was performed by a surgeon (E.B.)
licensed to work with experimental animals, and standard
surgical techniques were used. General anesthesia was
administered using a mixture of 40 mg/kg ketamine-HCl
(Alfamine IM, Alfasan International B.V., Woerden, The
Netherlands) and 5 mg/kg xylazine HCL (Alfazyne 2% IM,
Alfasan International B.V.). Animals were fixed in standard
posture, and the distal surface of their right and left femurs
was shaved and disinfected with 70% alcohol solution. To
reach the distal surface of the femur, 15e20 mm skin and
subcutaneous tissue dissection was performed parallel to
the long axis using a No. 15 scalpel. Two standard bone
defects with a diameter of 3 mm were created using round
drills (Gebr. Brasseler GmbH & Co. KG., Lemgo, Germany)
in both the right and left femur of each experimental
subject under physiological serum irrigation. The 3  3
critical-sized defect was based on a previous study.19
VEGF 165, which had been isolated from rat blood at the
Experimental Medicine Research Institute (EMRI, Istanbul
University), was stored in sterile tubes in cold chain and
then brought to room temperature before use. Briefly,
pcDNA3.1 plasmids were cloned and subjected to an
electro-transfer procedure. Then, a toxin-free plasmid was
produced, and the final VEGF plasmid was synthesized in a
cell culture.
Using a predefined random order, each rat’s four defects
were filled with the following: (1) BA with a granule size of
500e1000 mm and a porosity of 90% (Bone Ceramic; Strau-
mann, Basel, Switzerland; BA group); (2) VEGF alone; (3)
VEGF and BA in combination (VEGF þ BA group); or (4)
nothing, which served as a control (Figure 1).
Following the application of the materials, flaps were
repositioned with 3.0 silk sutures (Dogsan Medical, Trabzon,
Turkey). Mild compression was applied to the surgical site
using a gauze tampon. After the surgical procedure, a single
dose of tetracycline (Tetra 10 mg/kg intramuscularly; Mus-
tafa Nevzat _Ilac¸ Sanayii, _Istanbul, Turkey) was administered
to the experimental animals via the intraperitoneal route to
prevent postoperative infection. All experimental animals
were kept in metal cages in an automatized environment at
21  1C, a relative humidity of 40e60% and 12-hour dark/
light cycles until the sacrificing phase. Experimental animals
were fed with tap water and standard pellets.dothelial growth factor and biphasic calcium phosphate in the
Journal of Dental Sciences (2016), http://dx.doi.org/10.1016/
Figure 1 Visual appearance of the randomly allocated groups on the femoral defects: (A) VEGF group, (B) control group; (C) BA
group, and (D) BA þ VEGF group. BA Z biphasic alloplastic graft material; VEGF Z vascular endothelial growth factor.
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the 7th day and 10 at the end of the 14th day by adminis-
tering 135 mg/kg sodium pentothal via an intraperitoneal
route. Previous studies have found that this timing maxi-
mizes the effectiveness of VEGF.19 Femur bones were
separated from muscles with the help of a periosteum
elevator and from joints with the help of a scalpel, and they
were placed into a 10% formaldehyde solution and sent to a
histology laboratory for histomorphometric examination.
Initially, materials were fixed with a 10% buffered
formaldehyde solution for 48 hours. After fixation, a solu-
tion containing equal amounts of 50% formic acid and 20%
sodium citrate was prepared, and the samples were
decalcified for 3 days; they were then exposed to routine
tissue tracing. Thereafter, 5e7-mm sections were obtained
from paraffin blocks, stained with hematoxylin and eosin,
and examined under a light microscope.
During histomorphometric analysis, the following areas
were measured using the Olympus Analysis Five (Olympus
Corporation, Tokyo, Japan) image analysis program: newly
formed bone tissue; fibrotic connective tissue, including
the spaces resulting from loss of granulation tissue during
demineralization; inflammatory cells; and necrotic tissue.
The procedure was performed by measuring four separate
areas for each of the criteria in four sections obtained from
each block and by calculating a mean percentage according
to total magnification area.
Data were analyzed using SPSS for Windows 15.0 (SPSS
Inc., Chicago, IL, USA). Normality of the data distribution
was checked using the KolmogoroveSmirnov test. Inter-
group comparisons of measures that were not normally
distributed were performed using KruskaleWallis tests,
whereas paired comparisons were performed usingPlease cite this article in press as: Bedeloglu E, et al., Vascular en
endosseous healing of femoral defects: An experimental rat study,
j.jds.2016.04.005ManneWhitney U tests. Significance was evaluated at a
level of P < 0.05. A Bonferroni correction was made on
measurements derived from the same sample (P < 0.0125).
Results
Over the course of the healing period, no infection or
complication was observed in any of the experimental ani-
mals. However, a fracturewas detected in the defect area on
the 2nd day of the healing period in one animal. This animal
was replaced with another animal using the same protocol.
Upon retrieval of the bone specimens, it wasmacroscopically
observed that the integrity of the femur bones was pre-
served, and they showed no infectious reaction.
Histologic observation indicated that the graft particles
were in direct contact with the host bone, with new bone
growing into the graft-maintained area. This was more
clearly seen in the samples from Day 14 than in those from
Day 7. Bone deposition was evident at both time points.
New bone tissue was integrated with fibrous tissue areas
and residual graft particles, indicating graft resorption, in
the VEGF and BAþ VEGF groups (Figures 2 and 3).
Histomorphometric analysis
Measured values of inflammation, necrosis, fibrosis and new
bone formation areas of the groups on Day 7 and Day 14 are
provided in Tables 1 and 2.
At both time intervals, inflammation and necrosis were
significantly lower in the VEGF groups than in other groups
(mean  SD, 19.4 11.16% and 8.86 1.11% inflammation;
P < 0.001; 5.56 1.16% and 1.01 0.86% necrosis, P < 0.001dothelial growth factor and biphasic calcium phosphate in the
Journal of Dental Sciences (2016), http://dx.doi.org/10.1016/
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measured in the VEGF group on Day 7 (45.54 9.56%) was
significantly higher than in other groups (P < 0.001). On Day
7, the rate of new bone formation was similar across the BA,
VEGF and BAþ VEGF groups (33.10 13.79%, 46.60 5.0%,
and 43.40 8.00%, respectively) but was significantly lower
in the control group (16.2 3.42%, P < 0.0001). From Day 7
to Day 14, a statistically significant decrease in inflammation
and necrosis was evident in all groups. Fibrosis and new bone
formation showed a statistically significant increase on Day
14, except in the VEGF group. On Day 14, differences were
no longer discernable between the groups. The highest new
bone formation percentage was observed in the BA þ VEGF
group (60.6 16.15%), but the differences were not signifi-
cant (Figure 4).Discussion
The regenerative effect of VEGF and BA applied to critical-
sized defects in rat femurs was analyzed in this histologic
and histomorphometric study. The treatment groups
showed meaningful differences in bone formation and
related healing variables (inflammation, necrosis, and
fibrosis).
The primary goal of the augmentation method is to
replace lost bone with living bone tissue so that modern
rehabilitation treatments (such as osseointegrated implants
or tissue-born prosthesis) can be undertaken. Therefore,
any graft material placed into the lost bone volume needs
to be vascularized internally to allow cellular infiltrationFigure 2 Histologic samples from animals that have healed for 1
observed in the control defect; original magnification 200. (B) C
VEGF group; original magnification 100. (C) New bone depositio
magnification 400. (D) Active osteoid deposition on the graft ma
Please cite this article in press as: Bedeloglu E, et al., Vascular en
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j.jds.2016.04.005and bone cell migration. Especially in the oral cavity, this
process is frequently hampered by poor soft tissue coverage
and dehiscence, exposing the graft material to the oral
cavity and resulting in complete loss of the grafting mate-
rial or insufficient bone fill.20 VEGF may actively contribute
to this healing process by enhancing vascularization and
soft tissue proliferation on the cellular level.21 The results
of this study also showed that, when compared to a control
group, early-term new bone formation can be enhanced by
the use of VEGF.
Reis-Filho and colleagues22 extracted rat second molars
and investigated the influence of a similar allograft on VEGF
extraction. Maximum VEGF extraction was observed in the
1st week and 2nd week.22 Wang and colleagues conducted a
controlled study in a rabbit model and created 15-mm
critical-sized segmental defects in the femur, which were
filled with autologous grafts, b-tricalcium phosphate (b-
TCP), and vascular bundles. They stated that VEGF was
effective in both angiogenesis and ossification, particularly
in the first 3 weeks.23 Kleinheinz et al24 created a model of
mandibular bicortical defects in 56 rabbits and divided
them into two groups. In the first group, defects were left
empty or were filled with type-I collagen, whereas the
defects in the second group were filled with a collagen
matrix and recombinant human VEGF. No significant dif-
ference was observed between the test and control groups
in terms of new bone formation, but significantly higher
bone density was observed in the test group.24 To improve
bone gain further, Yonamine and colleagues25 placed a
polylacticeglycolic acid membrane over calvarial defects
treated with VEGF microspheres in rats. Radiological andweek; hematoxylin and eosin staining: (A) large trabeculae are
hondral ossification is characterized with fibrosis tissue in the
n around the graft material (arrow) in the BA group; original
terial (arrow) in BAþ VEGF group; original magnification 100.
dothelial growth factor and biphasic calcium phosphate in the
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Figure 3 Histologic samples from animals that have healed for 2 weeks; hematoxylin and eosin staining. (A) Thick bone
trabeculae surrounded by active connective tissue in the control group; original magnification 200. (B) New bone trabeculae in
the defect region surrounded by numerous blood vessels; original magnification 200. (C) The graft material is surrounded by new
bone deposition (arrow); original magnification 200. (D) Fibrotic tissues are being replaced by new bone tissue (arrow) surrounded
by large blood vessels; original magnification 200.
Table 1 Inflammation, necrosis, fibrosis and new bone values at the 7th day.
Day 7
Inflammation Necrosis Fibrosis New bone
P < 0.001 P < 0.001 P < 0.001 P < 0.001
Control 44.3  12.2a NS 21.1  10.2e NS 19.4  4, 3i NS 16.2  3.4m n, o, p
BA 40.7  12.2b NS 21.1  9.5f NS 29.6  13.9j NS 33.1  13.7n NS
VEGF 29.2  15.0c a, b, d 21.1  9.5g e, f, h 46.1  6.2k i, j, l 46.6  5.0o NS
BAþ VEGF 40.6  11.2d NS 19.4  4.3h NS 25.9  13.8l NS 43.4  8.0p NS
Pairwise statistical comparisons of the mentioned variables are expressed as letters (a, b, c, and d for the inflammation variable; e, f, g,
and h for the necrosis variable; i, j, k, and l for the fibrosis variable; and m, n, o, and p for the new bone variable in the control, BA,
VEGF, and BAþ VEGF groups, respectively).
BA Z biphasic alloplastic graft material; NS Z not statistically significant; VEGF Z vascular endothelial growth factor.
Table 2 Inflammation, necrosis, fibrosis, and new bone values at the 14th day.
Day 14
Inflammation Necrosis Fibrosis New bone
P < 0.001 P < 0.001 P < 0.001 P < 0.001
Control 4.5  6.0 NS 1.4  2.9 NS 45.8  4.1 NS 46.3  5.0 NS
BA 9.7  2.7 NS 1.6  2.5 NS 38.1  11.4 NS 55.6  14.1 NS
VEGF 7.6  2.5 NS 0.9  1.9 NS 46.6  4.5 NS 53.9  13.3 NS
BAþ VEGF 12.6  7.8 NS 8.7  2.8 NS 40.1  7.6 NS 60.6  16.1 NS
BA Z biphasic alloplastic graft material; NS Z not statistically significant; VEGF Z vascular endothelial growth factor.
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Figure 4 The rate of healing variables (inflammation, necrosis, and fibrosis and new bone formation) on Day 7 and Day 14.
Pairwise statistical comparisons of the mentioned variables are expressed as letters for easy identification (a, b, c, and d for the
inflammation variable; e, f, g, and h for the necrosis variable; i, j, k, and l for the fibrosis variable; and m, n, o, and p for the new
bone variable in the control, BA, VEGF, and BAþ VEGF groups, respectively). BA Z biphasic alloplastic graft material;
VEGF Z vascular endothelial growth factor.
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+ MODELhistological evaluations revealed thick mature bone
regeneration when VEGF was used in combination with a
polylacticeglycolic acid membrane.25 These results
corroborate the outcomes of the present study, and it can
be concluded that VEGF may enhance new bone formation
at the very early stages of healing.
The time frame over which VEGF is effective was also
investigated. It has been demonstrated that secretion of
VEGF was limited to the early stages (1e3 weeks) of
healing.26e28 Accordingly, the present study’s sample
retrieval schedule was employed to investigate the
behavior of VEGF when combined with an alloplast (BA).
Such alloplasts (especially calcium phosphates) have
been used widely because autologous grafts are difficult to
obtain in sufficient quantity and can cause complications in
the donor area. Alloplasts are inexpensive and lack the risk
of disease transfer.29,30 Furthermore, they can be easily
combined with various regeneration-inducing growth fac-
tors, including VEGF. This may be significant because allo-
plasts alone are only osteoconductive and frequently heal
by stimulating surrounding tissue growth.21 The main core
of alloplasts usually remains intact due to insufficient
vascularization and reach of extracellular fluids.22,31
Due to the disadvantages of HA alone, such as its fragile
surface characteristics and irregular biodegradation, the
use of b-TCP graft material in combination with HA has
become widespread.9,32 The BA material used in thePlease cite this article in press as: Bedeloglu E, et al., Vascular en
endosseous healing of femoral defects: An experimental rat study,
j.jds.2016.04.005present study consisted of a combination of HA and b-TCP
at ratios of 60% and 40%, respectively. This combination has
proven to be safe and optimal for bone defects such as
extraction sockets, periodontal and peri-implant regener-
ation and endodontic surgery.6,33 It has been reported that
this graft material acts like a skeleton for bone regenera-
tion, does not interact with the physiological bone depo-
sition process, and has high biocompatibility.2,34 Due to the
amorphous nature and bulk application of these materials,
complete bone replacement has not been achieved, espe-
cially in the middle region of the material.7,34,35 The pre-
sent histologic observation suggests that the application of
VEGF seems to increase vascular penetration and expedite
bone replacement in the BA body. This approach may
constitute a basis for the improvement of related
alloplasts.
Within the limits of this study, it can be concluded that
VEGF makes a significant contribution to recovery and
osteogenesis in the early stages of bone defect healing, and
its combination with an osteoconductive alloplast (BA) may
further enhance new bone formation.Conflicts of interest
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